Bella Devaleenal Daniel

I have been involved in clinical research for more than 18 years, was involved in AIDS research including land mark trials such as ACTG 5175 and HPTN 052 which were key players in current treatment guidelines. Currently working in TB research since 2015, involved in clinical trials for shortening treatment regimen for drug sensitive and resistant TB, optimal dosing of anti-tuberculous therapy for TB paediatric TB meningitis, use of adjuvants such as Vitamin C for host directed therapy in TB management, TB vaccine for prevention among household contacts and implementation research to improve airborne infection control practices.

Key research areas are shortening TB treatment, TB prevention, Airborne infection control  

Paradkar MS, Devaleenal DB, Mvalo T, Arenivas A, Thakur KT, Wolf L, Nimkar S, Inamdar S, Giridharan P, Selladurai E, Kinikar A. Randomized, Clinical Trial of High Dose Rifampicin with or without Levofloxacin versus Standard of Care for Paediatric Tuberculous Meningitis: The TBM-KIDS Trial. Clinical Infectious Diseases. 2022 Mar 15. IF – 9.75 

Padmapriyadarsini C, Devaleenal B, Ponnuraja C, Ramraj B, Singla R, Parmar M, Mattoo S, Mandal S. Randomised trial to evaluate the effectiveness and safety of varying doses of linezolid with bedaquiline and pretomanid in adults with pre-extensively drug-resistant or treatment intolerant/non-responsive multidrug-resistant pulmonary tuberculosis: study protocol. BMJ open. 2022 Aug 1;12(8):e058606. IF- 3.006 

Daniel BD, Grace GA, Natrajan M. Tuberculous meningitis in children: Clinical management & outcome. The Indian journal of medical research. 2019 Aug;150(2):117. IF- 5.274 

Paradkar M, Devaleenal DB, Mvalo T, Arenivas A, Thakur KT, Afrin S, Giridharan P, Selladurai E, Kinikar A, Valvi C, Gupta A. Challenges in conducting trials for pediatric tuberculous meningitis: lessons from the field. The International Journal of Tuberculosis and Lung Disease. 2019 Oct 1;23(10):1082-9. IF-3.4 

Daniel DB, Ramachandran G, Swaminathan S. The challenges of pharmacokinetic variability of first-line anti-TB drugs. Expert Rev Clin Pharmacol. 2017;10:47–58.